Team "Cognitive Neuropsychology & Physiopathology of Schizophrenia"
Director: Anne Giersch
Anne Giersch is a research director at INSERM. The team aims to understand the pathophysiology of schizophrenia in order to develop new therapies. Schizophrenia is currently only defined by clinical symptoms. Studying cognitive disorders is aimed at establishing links between the disease and neurobiology. In 2016, the team published a study showing that schizophrenic patients have greater sensitivity to pain than the scientific community has believed for years. EURIDOL enables the team to treat pain in schizophrenia and collaborate on their applied research. This partnership also helps raise questions about other risk factors such as cannabis, known to relieve chronic pain. Dr. Laurence Lalanne especially focused on these questions through research on addiction in Anne Giersch's laboratory.
Inserm Website of Team "Cognitive Neuropsychology & Physiopathology of Schizophrenia"